Valproate is the best mood stabilizer for a patient who drinks alcohol
For a patient with bipolar disorder who drinks alcohol, valproate (divalproex sodium) is the recommended mood stabilizer based on the strongest available evidence. This is the only mood stabilizer with randomized controlled trial data specifically demonstrating efficacy in patients with comorbid bipolar disorder and alcohol use disorder 1, 2.
Evidence Supporting Valproate
The landmark double-blind, placebo-controlled trial by Salloum et al. demonstrated that valproate therapy:
- Significantly decreased the proportion of heavy drinking days (p=0.02)
- Reduced drinks per heavy drinking day when medication adherence was factored in (p=0.02)
- Showed a dose-response relationship, with higher serum concentrations correlating with better alcohol use outcomes
- Improved liver function markers (lower gamma-glutamyl transpeptidase levels) compared to placebo 1
Importantly, valproate addresses both the mood symptoms AND the alcohol use, making it uniquely suited for this dual diagnosis 2, 3.
Why Other Mood Stabilizers Are Less Appropriate
Lithium
- Avoid lithium in active drinkers. Evidence suggests lithium may not be effective in bipolar patients with comorbid substance use 3
- Alcohol consumption makes lithium levels unpredictable and increases toxicity risk
- Dehydration from drinking exacerbates lithium toxicity potential
Lamotrigine
- No evidence for efficacy in alcohol use disorder
- Paradoxical risk: Lamotrigine is the most common mood stabilizer associated with treatment-emergent mania (58% of reported cases), particularly in patients already on other mood stabilizers 4
- Takes weeks to titrate safely, delaying therapeutic benefit
Quetiapine
- Mixed evidence: One controlled trial showed it reduced depressive symptoms but did not modify alcohol use 5
- While case reports suggest possible benefit 6, the controlled data show no impact on drinking 5
- Not a first-line mood stabilizer
Practical Implementation via Telehealth
Initial Assessment Priorities
Before prescribing, assess via video visit:
- Current drinking pattern: Quantity, frequency, time of last drink
- Withdrawal risk: Tremor, sweating, anxiety, history of seizures or delirium tremens
- Bipolar phase: Manic, depressed, mixed, or euthymic
- Liver function baseline: Essential for valproate monitoring
- Pregnancy status in women of childbearing age (valproate is teratogenic)
Dosing Strategy
- Start valproate 250-500 mg twice daily
- Target therapeutic level: 50-125 mcg/mL
- Titrate based on clinical response and serum levels
- Monitor adherence closely—higher serum concentrations predict better outcomes 1
Critical Monitoring via Telehealth
Baseline labs (before starting):
- Complete blood count
- Liver function tests (AST, ALT, GGT)
- Pregnancy test
Follow-up monitoring (every 3-6 months):
- Valproate serum levels
- Liver function tests
- Complete blood count
- Clinical assessment of mood and drinking patterns
Address Alcohol Use Concurrently
- Do not wait for abstinence before starting valproate—the medication helps reduce drinking 1
- If patient shows signs of acute alcohol withdrawal (tremor, tachycardia, diaphoresis), defer valproate and manage withdrawal first with benzodiazepines 7
- Consider adjunctive naltrexone for additional alcohol craving reduction 2, 3
- Integrate psychosocial support: telehealth-delivered motivational interviewing or cognitive behavioral therapy enhances outcomes 8, 9
Common Pitfalls to Avoid
- Don't defer treatment waiting for abstinence—valproate works in actively drinking patients 1
- Don't use lithium as first-line in this population due to safety concerns and lack of efficacy data
- Don't assume mood symptoms are substance-induced without a trial of treatment—many patients have primary bipolar disorder that requires ongoing management 10
- Don't neglect liver monitoring—both alcohol and valproate affect hepatic function
- Don't prescribe valproate to women of childbearing potential without contraception and thorough counseling about teratogenicity
When to Consider Alternatives
If valproate fails or is contraindicated:
- Naltrexone can be added for alcohol craving (most effective anticraving agent in severe mental illness) 3
- Integrated group therapy targeting substance use first, then mood symptoms 2
- Consider clozapine if psychotic features present (emerging evidence for dual diagnosis) 3
The telehealth format is appropriate for this assessment and ongoing management, as behavioral health conditions benefit substantially from remote care access 8.